Candel Therapeutics, Inc. (CADL) › Cash & EquivalentsCandel Therapeutics, Inc. (CADL) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2020-12-31: $35.05M2021-12-31: $82.64M2022-12-31: $70.06M2023-12-31: $35.41M2024-12-31: $102.65M2025-12-31: $119.73M$119.73M2020-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$119.73M+16.6%2026-03-12Balance as of period end2024-12-31$102.65M+189.9%2026-03-12Balance as of period end2023-12-31$35.41M-49.5%2025-03-13Balance as of period end2022-12-31$70.06M-15.2%2024-03-28Balance as of period end2021-12-31$82.64M+135.8%2023-03-30Balance as of period end2020-12-31$35.05M—2022-03-29Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)